title: Can acute rejection be prevented in SPK transplantation?
authors.affiliation: Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Highland Professional Building 5th Floor, 1801 NW 9th Avenue, Rm. 521, Miami, FL 33136, USA. gburke@med.miami.edu
authors.forename: George  W
authors.initials: G
authors.lastname: Burke
authors.forename: G
authors.initials: G
authors.lastname: Ciancio
authors.forename: J
authors.initials: J
authors.lastname: Figueiro
authors.forename: L
authors.initials: L
authors.lastname: Olson
authors.forename: C
authors.initials: C
authors.lastname: Gomez
authors.forename: A
authors.initials: A
authors.lastname: Rosen
authors.forename: K
authors.initials: K
authors.lastname: Suzart
authors.forename: J
authors.initials: J
authors.lastname: Miller
mesh_terms: D000208:Acute Disease; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D020123:Sirolimus / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus